Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML-Reference-Cited by-同舟云学术

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML

Published:2018-07-19 Issue:1 Volume:33 Page:205-216
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Niyongere Sandrine,Lucas Nolwenn,Zhou Jun-Min,Sansil Samer,Pomicter Anthony D.,Balasis Maria E.^ORCID,Robinson John,Kroeger Jodi,Zhang Qing,Zhao Yu Long,Ball Markus,Komrokji Rami,List Alan,Deininger Michael W.,Fridley Brooke L.,Santini Valeria,Solary Eric,Padron Eric

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0203-0.pdf

Reference51 articles.

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.

3. Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408–17.

4. Ball M, List AF, Padron E. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. Blood. 2016;128:2381–7.

5. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemia;2024-03-13

2. Targeting Heterochromatin Eliminates Malignant Hematopoietic Stem and Progenitor Cells in Chronic Myelomonocytic Leukemia Through Reactivation of Retroelements and Innate Immune pathways;2024-02-02

3. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy;Cell Reports Medicine;2023-12

4. Treatment Algorithm of CMML and Other Adult MDS/MPN Subtypes;Pathogenesis and Treatment of Leukemia;2023

5. The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes;BMC Cancer;2022-09-24